Matches in Wikidata for { <http://www.wikidata.org/entity/Q96580163> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q96580163 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96580163 description "scientific article published on 01 June 2020" @default.
- Q96580163 description "wetenschappelijk artikel" @default.
- Q96580163 description "наукова стаття, опублікована 1 червня 2020" @default.
- Q96580163 name "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 name "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 type Item @default.
- Q96580163 label "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 label "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 prefLabel "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 prefLabel "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 P1433 Q96580163-C15C0A18-952C-48E5-8496-EBEC22ED7118 @default.
- Q96580163 P1476 Q96580163-3DBF53A7-3C7E-484F-BBDE-329E2F27246E @default.
- Q96580163 P2093 Q96580163-08201515-FE32-49AD-81D1-EF9633011D49 @default.
- Q96580163 P2093 Q96580163-36AD07B2-21B7-4CB4-80A4-D4B55099D989 @default.
- Q96580163 P2093 Q96580163-5ACE0A51-2A41-4AF0-A7C9-FFEA69D2639C @default.
- Q96580163 P2093 Q96580163-6BE9DA40-0812-4794-9327-50C96B15A00D @default.
- Q96580163 P2093 Q96580163-78C2E6D6-0374-41F4-91A3-A9FC8D703534 @default.
- Q96580163 P2093 Q96580163-7E88ADE0-5651-4DAB-AAE5-60C963BA2E9A @default.
- Q96580163 P2093 Q96580163-93914A35-849A-4E3B-BB32-5C9BEB632502 @default.
- Q96580163 P2093 Q96580163-962CCE25-7070-40D3-8CFD-670A611B7957 @default.
- Q96580163 P2093 Q96580163-D8BBBD51-4619-4DAA-9C84-8E6715FC829F @default.
- Q96580163 P304 Q96580163-1DC9A192-E7CB-4001-A397-ABB43CF522D9 @default.
- Q96580163 P31 Q96580163-719CF725-E7C9-4288-BFA1-CE13F74A94B7 @default.
- Q96580163 P356 Q96580163-AAF3423A-612E-4578-B090-77D30A74C4CA @default.
- Q96580163 P433 Q96580163-B31E2F41-25CE-49D4-8D75-6A5442568CAB @default.
- Q96580163 P478 Q96580163-AD075951-67A4-41E4-BE5A-79259548F7FA @default.
- Q96580163 P577 Q96580163-57994EC3-9B8E-4AF5-90C2-CFE27E40CFAC @default.
- Q96580163 P698 Q96580163-2EDC8C62-815F-4E83-A3D2-C60639862C7B @default.
- Q96580163 P921 Q96580163-86DC606E-4E91-437B-8671-92B8150DFCEC @default.
- Q96580163 P921 Q96580163-E3C3BFB7-A196-4333-8AF7-E931AEF82F63 @default.
- Q96580163 P932 Q96580163-CFE4267B-7471-456A-AD2F-9F2C4C531616 @default.
- Q96580163 P356 BLOODADVANCES.2019001367 @default.
- Q96580163 P698 32556281 @default.
- Q96580163 P1433 Q84365144 @default.
- Q96580163 P1476 "KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure" @default.
- Q96580163 P2093 "Akash Nahar" @default.
- Q96580163 P2093 "Craig H Moskowitz" @default.
- Q96580163 P2093 "Jean-Marie Michot" @default.
- Q96580163 P2093 "John Kuruvilla" @default.
- Q96580163 P2093 "Patricia Marinello" @default.
- Q96580163 P2093 "Philippe Armand" @default.
- Q96580163 P2093 "Pier Luigi Zinzani" @default.
- Q96580163 P2093 "Vincent Ribrag" @default.
- Q96580163 P2093 "Ying Zhu" @default.
- Q96580163 P304 "2617-2622" @default.
- Q96580163 P31 Q13442814 @default.
- Q96580163 P356 "10.1182/BLOODADVANCES.2019001367" @default.
- Q96580163 P433 "12" @default.
- Q96580163 P478 "4" @default.
- Q96580163 P577 "2020-06-01T00:00:00Z" @default.
- Q96580163 P698 "32556281" @default.
- Q96580163 P921 Q13896859 @default.
- Q96580163 P921 Q209369 @default.
- Q96580163 P932 "7322954" @default.